Medicare Expands Coverage for Personalis’ NeXT Personal Test to Monitor Immunotherapy in Late-Stage Solid Tumors

Event summary

  • Medicare expanded coverage for Personalis’ NeXT Personal test to include immunotherapy monitoring for late-stage solid tumors.
  • The decision follows clinical evidence from a study with VHIO demonstrating the test’s ability to predict treatment outcomes.
  • NeXT Personal’s ultrasensitivity allows for real-time evaluation of treatment response, addressing challenges like pseudoprogression in immunotherapy.
  • The test tracks up to ~1,800 patient-specific mutations, providing a high-resolution view of tumor dynamics.

The big picture

This coverage expansion positions Personalis as a key player in precision oncology, particularly in the growing immunotherapy market. With hundreds of thousands of patients receiving immunotherapy annually, the ability to monitor treatment response in real-time addresses a critical gap in cancer care. The decision underscores the shift toward molecular diagnostics in managing complex treatment pathways, potentially influencing broader healthcare policy and reimbursement strategies.

What we're watching

Adoption Pace
How quickly physicians and patients will integrate NeXT Personal into immunotherapy treatment plans.
Competitive Response
Whether competitors will develop similar ultrasensitive MRD tests to challenge Personalis’ position.
Regulatory Expansion
The likelihood of Medicare extending coverage to additional indications beyond late-stage solid tumors.

Related topics

Biotechnology